MX2010006731A - Uso de un componente neurotoxico de un complejo de toxina de clostridium botulinum para reducir o prevenir efectos secundarios. - Google Patents
Uso de un componente neurotoxico de un complejo de toxina de clostridium botulinum para reducir o prevenir efectos secundarios.Info
- Publication number
- MX2010006731A MX2010006731A MX2010006731A MX2010006731A MX2010006731A MX 2010006731 A MX2010006731 A MX 2010006731A MX 2010006731 A MX2010006731 A MX 2010006731A MX 2010006731 A MX2010006731 A MX 2010006731A MX 2010006731 A MX2010006731 A MX 2010006731A
- Authority
- MX
- Mexico
- Prior art keywords
- botulinum toxin
- clostridium botulinum
- toxin complex
- side effects
- neurotoxic component
- Prior art date
Links
- 108030001720 Bontoxilysin Proteins 0.000 title abstract 4
- 241000193155 Clostridium botulinum Species 0.000 title abstract 4
- 229940053031 botulinum toxin Drugs 0.000 title abstract 4
- 231100000189 neurotoxic Toxicity 0.000 title abstract 3
- 230000002887 neurotoxic effect Effects 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 241001465754 Metazoa Species 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000001713 cholinergic effect Effects 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- 210000003499 exocrine gland Anatomy 0.000 abstract 1
- 230000001815 facial effect Effects 0.000 abstract 1
- 230000030214 innervation Effects 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Neurosurgery (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US901007P | 2007-12-21 | 2007-12-21 | |
| EP07024961A EP2072039A1 (en) | 2007-12-21 | 2007-12-21 | Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects |
| PCT/EP2008/010782 WO2009080272A1 (en) | 2007-12-21 | 2008-12-17 | Use of a neurotoxic component of a clostridium botulinum toxin complex to reduce or prevent side effects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010006731A true MX2010006731A (es) | 2010-08-16 |
Family
ID=39401018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010006731A MX2010006731A (es) | 2007-12-21 | 2008-12-17 | Uso de un componente neurotoxico de un complejo de toxina de clostridium botulinum para reducir o prevenir efectos secundarios. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100331259A1 (enExample) |
| EP (2) | EP2072039A1 (enExample) |
| JP (1) | JP2011506511A (enExample) |
| KR (1) | KR20100107475A (enExample) |
| CN (1) | CN101917960A (enExample) |
| AR (1) | AR069806A1 (enExample) |
| AU (1) | AU2008340713A1 (enExample) |
| CA (1) | CA2709644A1 (enExample) |
| IL (1) | IL206423A0 (enExample) |
| MX (1) | MX2010006731A (enExample) |
| RU (1) | RU2010130542A (enExample) |
| WO (1) | WO2009080272A1 (enExample) |
| ZA (1) | ZA201004393B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10792344B2 (en) * | 2006-06-29 | 2020-10-06 | Merz Pharma Gmbh & Co. Kgaa | High frequency application of botulinum toxin therapy |
| US9161970B2 (en) * | 2007-12-12 | 2015-10-20 | Allergan, Inc. | Dermal filler |
| US9480731B2 (en) * | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
| US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| US9901627B2 (en) | 2014-07-18 | 2018-02-27 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| WO2018146550A1 (en) * | 2017-02-10 | 2018-08-16 | De Maio Domingos Mauricio | Methods and systems for preventing, correcting, transforming, and modifying facial, aesthetics, and consulting patients regarding the same |
| DE102019215585B4 (de) * | 2019-10-10 | 2022-02-17 | KCM Egészségügyi és Tudományos Korlátolt Felelösségü Társaság | Verfahren zur prävention von strahlenschäden in humanen drüsen |
| US11241479B2 (en) | 2019-10-18 | 2022-02-08 | Penland Foundation | Treatment methods using botulinum toxins |
| US10973873B1 (en) | 2019-10-18 | 2021-04-13 | Penland Foundation | Treatment of asthma using botulinum toxin |
| US11090371B1 (en) * | 2019-10-18 | 2021-08-17 | Penland Foundation | Treatment of cirrhosis using botulinum toxin |
| US11925677B2 (en) | 2021-07-12 | 2024-03-12 | Penland Foundation | Treatment of diabetes and chronic pancreatitis using botulinum toxin |
| US10967052B1 (en) | 2019-10-18 | 2021-04-06 | Penland Foundation | Treatment of dyslexia using botulinum toxin |
| AU2020365148B2 (en) | 2019-10-18 | 2022-10-27 | Penland Foundation | Botulinum toxin for use in treatment |
| US11738071B2 (en) | 2021-07-12 | 2023-08-29 | Penland Foundation | Treatment of acute and chronic kidney disease |
| US10987411B1 (en) | 2019-10-18 | 2021-04-27 | Penland Foundation | Treatment of chronic obstructive pulmonary disease using botulinum toxin |
| US10960061B1 (en) * | 2019-10-18 | 2021-03-30 | Penland Foundation | Treatment of amyotrophic lateral sclerosis using botulinum toxin |
| US10960060B1 (en) | 2019-10-18 | 2021-03-30 | Penland Foundation | Treatment of cardiac arrhythmia using botulinum toxin |
| KR102397708B1 (ko) * | 2020-04-29 | 2022-05-16 | 한국화학연구원 | 탄닌산을 포함하는 보툴리눔 독소 약제학적 조성물 |
| CN116096399A (zh) * | 2020-06-03 | 2023-05-09 | 米奥托克斯有限责任公司 | 用于治疗偏头痛病症的区带性和靶向方法和用途 |
| IL298399A (en) * | 2020-06-05 | 2023-01-01 | Merz Pharma Gmbh & Co Kgaa | Treatment of facial wrinkles with the botulinum toxin in high dose and low volume |
| KR102724650B1 (ko) | 2021-07-05 | 2024-11-01 | 주식회사 파마리서치바이오 | 클로스트리디움 보툴리눔 독소 복합체 단백질의 정제방법 |
| KR102724651B1 (ko) | 2021-07-08 | 2024-11-01 | 주식회사 파마리서치바이오 | 비-독소 단백질이 제거된 클로스트리디움 보툴리눔 신경독소 단백질의 정제방법 |
| KR102551301B1 (ko) | 2022-10-28 | 2023-07-03 | 주식회사 파마리서치바이오 | 보툴리눔 독소를 포함하는 안정한 액상 제제 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8187612B2 (en) * | 1993-12-28 | 2012-05-29 | Allergan, Inc. | Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle |
| EP1602379A1 (en) * | 1993-12-28 | 2005-12-07 | Allergan, Inc. | Botulinum toxin B for treating spastic muscle |
| US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
| US5756468A (en) * | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
| DE19925739A1 (de) * | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
| CA2494241C (en) | 2000-02-08 | 2011-06-14 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions |
| US6503653B2 (en) * | 2001-02-23 | 2003-01-07 | General Motors Corporation | Stamped bipolar plate for PEM fuel cell stack |
| JP3830766B2 (ja) * | 2001-03-09 | 2006-10-11 | 本田技研工業株式会社 | 燃料電池および燃料電池スタック |
| EP1491205A4 (en) * | 2002-03-29 | 2007-04-25 | Chemo Sero Therapeut Res Inst | MEANS FOR THE TREATMENT OF HYPERMYOTONIA |
| US20040115222A1 (en) * | 2002-09-06 | 2004-06-17 | Michael Kane | Method for reduction of wrinkles |
| JP2005089336A (ja) * | 2003-09-12 | 2005-04-07 | Tokyo Univ Of Agriculture | Ｄ型ボツリヌス神経毒素の精製法 |
| BRPI0513850A (pt) * | 2004-07-26 | 2008-05-20 | Merz Pharma Gmbh & Co Kgaa | composição terapêutica com uma neurotoxina botulìnica |
| GB2426702A (en) * | 2004-10-28 | 2006-12-06 | Ipsen Ltd | Pharmaceutical composition comprising botulinum neurotoxin |
| DE102004043009A1 (de) * | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| AR061669A1 (es) | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
-
2007
- 2007-12-21 EP EP07024961A patent/EP2072039A1/en not_active Withdrawn
-
2008
- 2008-12-17 US US12/735,144 patent/US20100331259A1/en not_active Abandoned
- 2008-12-17 CN CN2008801218887A patent/CN101917960A/zh active Pending
- 2008-12-17 KR KR1020107016383A patent/KR20100107475A/ko not_active Withdrawn
- 2008-12-17 EP EP08864233A patent/EP2231107A1/en not_active Withdrawn
- 2008-12-17 MX MX2010006731A patent/MX2010006731A/es not_active Application Discontinuation
- 2008-12-17 WO PCT/EP2008/010782 patent/WO2009080272A1/en not_active Ceased
- 2008-12-17 CA CA2709644A patent/CA2709644A1/en not_active Abandoned
- 2008-12-17 JP JP2010538453A patent/JP2011506511A/ja active Pending
- 2008-12-17 RU RU2010130542/15A patent/RU2010130542A/ru not_active Application Discontinuation
- 2008-12-17 AU AU2008340713A patent/AU2008340713A1/en not_active Abandoned
- 2008-12-18 AR ARP080105529A patent/AR069806A1/es not_active Application Discontinuation
-
2010
- 2010-06-16 IL IL206423A patent/IL206423A0/en unknown
- 2010-06-22 ZA ZA2010/04393A patent/ZA201004393B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR069806A1 (es) | 2010-02-17 |
| IL206423A0 (en) | 2010-12-30 |
| KR20100107475A (ko) | 2010-10-05 |
| CN101917960A (zh) | 2010-12-15 |
| CA2709644A1 (en) | 2009-07-02 |
| AU2008340713A1 (en) | 2009-07-02 |
| EP2231107A1 (en) | 2010-09-29 |
| EP2072039A1 (en) | 2009-06-24 |
| RU2010130542A (ru) | 2012-01-27 |
| ZA201004393B (en) | 2011-08-31 |
| WO2009080272A1 (en) | 2009-07-02 |
| US20100331259A1 (en) | 2010-12-30 |
| JP2011506511A (ja) | 2011-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010006731A (es) | Uso de un componente neurotoxico de un complejo de toxina de clostridium botulinum para reducir o prevenir efectos secundarios. | |
| DK2282766T3 (da) | Suturlinie-indgivelsesteknik med anvendelse af botulinumtoksiner | |
| MX342853B (es) | Tratamiento anti-envejecimiento de la piel. | |
| WO2008122049A3 (en) | Methods and compositions for reduction of side effects of therapeutic treatments | |
| BR112015007985A8 (pt) | uso do carboidrato galactose denteada para preparação de composições para tratamento de nefropatia diabética e de distúrbios associados, e suas composições | |
| AR065033A1 (es) | Metodos para prevenir y tratar trastornos neurodegenerativos | |
| TW200503751A (en) | Methods for treating sinus headache | |
| TR201901443T4 (tr) | Botulinum nanoemülsiyonları. | |
| MX2010000937A (es) | Tratamiento del trastorno por estrés postraumático. | |
| MY163119A (en) | Use of tenecteplase for treating acute ischemic stroke | |
| UA113849C2 (xx) | Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу | |
| SG10201906172XA (en) | Regulation of glucose metabolism using anti-cgrp antibodies | |
| EA200970154A1 (ru) | Косметические или дерматологические препараты, содержащие n-ацетилцистеин | |
| BR112013011259A2 (pt) | condições de tratamento associadas com nível aumentado de eotaxina com 25-hidroxivitamina d3 | |
| MX2022010186A (es) | Neurotoxinas botulinas para uso en terapia. | |
| PH12019502721A1 (en) | Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin | |
| UA108073C2 (ru) | 2,5-дизамещенные арилсульфонамидные антагонисты ccr3 | |
| IN2014CN03333A (enExample) | ||
| TW200738267A (en) | Methods of increasing lymphatic function | |
| WO2007087154A3 (en) | Methods for enhancing therapeutic effects of a neurotoxin | |
| MX339834B (es) | Regimen terapeutico y metodos para tratar o mejorar trastornos visuales asociados a deficiencia endogena de retinoide. | |
| EP2566502A4 (en) | METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION | |
| WO2010075444A3 (en) | Nasal formulations of metoclopramide | |
| WO2012173781A3 (en) | Methods of treating glucose metabolism disorders | |
| WO2014036105A3 (en) | Inhibitors of memapsin 2 cleavage for the treatment of alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |